ATE539743T1 - Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan - Google Patents

Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan

Info

Publication number
ATE539743T1
ATE539743T1 AT06769069T AT06769069T ATE539743T1 AT E539743 T1 ATE539743 T1 AT E539743T1 AT 06769069 T AT06769069 T AT 06769069T AT 06769069 T AT06769069 T AT 06769069T AT E539743 T1 ATE539743 T1 AT E539743T1
Authority
AT
Austria
Prior art keywords
macelignan
preventing
mediated conditions
treating ppar
ppar
Prior art date
Application number
AT06769069T
Other languages
English (en)
Inventor
Kyu-Lee Han
Jong-Hee Sohn
Ah-Jin Kim
Jeong-Han Choo
Jae-Young Lee
Jeong-Hwan Kim
Original Assignee
Newtree Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020050055539A external-priority patent/KR100627643B1/ko
Priority claimed from KR1020050056692A external-priority patent/KR20070001326A/ko
Application filed by Newtree Co Ltd filed Critical Newtree Co Ltd
Application granted granted Critical
Publication of ATE539743T1 publication Critical patent/ATE539743T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06769069T 2005-06-27 2006-06-27 Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan ATE539743T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020050055539A KR100627643B1 (ko) 2005-06-27 2005-06-27 제 2 형 당뇨병 치료 또는 예방용 약제학적 조성물
KR1020050056692A KR20070001326A (ko) 2005-06-29 2005-06-29 핵수용체 피피에이알감마의 신규한 리간드
KR20050087991 2005-09-22
PCT/KR2006/002493 WO2007001150A2 (en) 2005-06-27 2006-06-27 Method for preventing and treating conditions mediated by ppar using macelignan

Publications (1)

Publication Number Publication Date
ATE539743T1 true ATE539743T1 (de) 2012-01-15

Family

ID=37595537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06769069T ATE539743T1 (de) 2005-06-27 2006-06-27 Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan

Country Status (7)

Country Link
US (1) US7902254B1 (de)
EP (1) EP1948161B1 (de)
JP (1) JP5416969B2 (de)
CN (1) CN102036662B (de)
AT (1) ATE539743T1 (de)
ES (1) ES2380556T3 (de)
WO (1) WO2007001150A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100844376B1 (ko) * 2007-02-07 2008-07-07 한국화학연구원 육두구 추출물 또는 이로부터 분리된 활성 화합물을포함하는 골다공증 예방 또는 치료용 조성물
KR101404398B1 (ko) * 2007-06-20 2014-06-09 (주)뉴트리 주름개선 화장료 조성물
CN101827579B (zh) * 2007-10-17 2013-01-23 生物关怀有限公司 木酚素系化合物或含有该化合物的肉豆蔻提取物或肉豆蔻假种皮提取物的新用途
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
WO2010064845A2 (en) * 2008-12-02 2010-06-10 Dong Wha Pharm. Co., Ltd. The pharmaceutical composition or the functional foods for the treatment or prevention of obesity comprising the extract from myristica fragrans houttuyn
KR101062670B1 (ko) * 2009-06-01 2011-09-06 (주)아모레퍼시픽 2,5-비스-아릴-3,4-디메틸테트라하이드로퓨란 리그난을 유효성분으로 포함하는 에이엠피케이의 활성화에 의해 매개되는 비만 관련 질환의 예방 또는 치료용 조성물
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
US9066880B2 (en) 2010-04-08 2015-06-30 Symrise Ag Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105153107B (zh) * 2015-08-21 2017-06-06 河南大学 一种促凝血肉豆蔻外壳有效成分及其提取分离方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200103250B (en) * 2000-01-20 2001-10-25 Irene Amiras The treatment of immunomodulatory related and other diseases or conditions.
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
ATE442365T1 (de) * 2003-05-20 2009-09-15 Novartis Pharma Gmbh N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
MXPA06003055A (es) * 2003-09-17 2006-05-31 Novartis Ag Compuestos organicos.
NZ546444A (en) * 2003-11-05 2009-09-25 Hoffmann La Roche Phenyl derivatives as PPAR agonists
US20080114058A1 (en) * 2005-01-07 2008-05-15 Jae-Kwan Hwang Use Of Lignan Compounds For Treating Or Preventing Inflammatory Disease
KR100679306B1 (ko) * 2005-03-31 2007-02-06 아미코젠주식회사 리그난계 화합물을 함유하는 뇌신경질환의 치료 또는예방용 약학적 조성물
US20100152209A1 (en) * 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function

Also Published As

Publication number Publication date
CN102036662A (zh) 2011-04-27
ES2380556T3 (es) 2012-05-16
JP5416969B2 (ja) 2014-02-12
EP1948161A4 (de) 2010-04-21
WO2007001150A2 (en) 2007-01-04
US20110071221A1 (en) 2011-03-24
JP2008543931A (ja) 2008-12-04
CN102036662B (zh) 2013-02-27
US7902254B1 (en) 2011-03-08
EP1948161A2 (de) 2008-07-30
EP1948161B1 (de) 2012-01-04

Similar Documents

Publication Publication Date Title
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
TW200420549A (en) Thiazole derivatives
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2006058016A3 (en) Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
TW200716547A (en) Piperidin-4-yl-amide derivatives
EP1627635A3 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen